When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease

Faculty: Dani Cabral, MD


Faculty: David Weisman, MD

As anti-amyloid therapies reshape the management of early symptomatic Alzheimer’s disease, timely recognition, accurate diagnosis, and appropriate patient selection are increasingly important in clinical practice. In this expert-led series, Dr. David Weisman and Dr. Dani Cabral explore practical approaches to identifying patients with mild cognitive impairment or mild dementia, confirming amyloid pathology using blood-based biomarkers, CSF testing, or amyloid PET, and determining eligibility for anti-amyloid therapy. Through a patient case and practical workflows, they examine key considerations for treatment selection and individualized risk assessment, including APOE genotype, baseline MRI findings, and pre-test probability, while reviewing clinical trial evidence for lecanemab and donanemab from Clarity AD. The faculty also address the recognition and management of amyloid-related imaging abnormalities (ARIA), infusion-related reactions, MRI surveillance, treatment interruption and reinitiation, and emergency considerations. Through the series, our experts offer practical guidance for integrating anti-amyloid therapies into clinical workflows and supporting shared decision-making, multidisciplinary coordination, and informed conversations with patients and care partners.